Pharma

Your Article Summary

See Latest Articles

Ilaris recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseases
Novartis, 07/27/09

The biotechnology medicine Ilaris (canakinumab) has passed another major milestone with a recommendation for approval in the European Union to treat patients with a life–long and potentially fatal auto–inflammatory disease called cryopyrin–associated periodic syndrome (CAPS). When approved, Ilaris will be the only treatment in the EU indicated for CAPS patients aged four years and older.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

What Makes a Generic Medication Generic?
Journal of Psychosocial Nursing and Mental Health Services, 12/18/09

Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09

Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09

 See all of Biotechnology

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals